Scholar Rock Holding (SRRK) Free Cash Flow Growth (3y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 31.42% |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -24.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.01% |
| Dec 31, 2025 | -36.25% |
| Sep 30, 2025 | -39.04% |
| Jun 30, 2025 | -29.84% |
| Mar 31, 2025 | -22.47% |
| Dec 31, 2024 | -14.50% |
| Sep 30, 2024 | -9.43% |
| Jun 30, 2024 | -17.77% |
| Mar 31, 2024 | -19.95% |
| Dec 31, 2023 | -19.92% |
| Sep 30, 2023 | -8.56% |
| Jun 30, 2023 | -17.48% |
| Mar 31, 2023 | -164.03% |
| Dec 31, 2022 | -19.41% |
| Sep 30, 2022 | -15.35% |
| Jun 30, 2022 | -30.25% |
| Mar 31, 2022 | -38.97% |
| Dec 31, 2021 | -37.62% |
| Sep 30, 2021 | -60.91% |
| Jun 30, 2021 | -36.67% |
| Mar 31, 2021 | -42.86% |
| Dec 31, 2020 | -50.45% |
| Sep 30, 2020 | -65.20% |